AEterna Zentaris Inc. (NASDAQ: AEZS)
AEterna Zentaris is having an incredibly rough day in the market today. While many are concerned, I’m seeing this as an opportunity. Today, we’ll talk about a key factor that the stock has going for it, what we’re seeing in the market today, and what we can expect to see from AEZS ahead.
Trade smarter and make more money with Tradespoon!
Why AEZS Declines Are An Opportunity
While some investors may be overwhelmingly concerned looking at the AEterna Zentaris stock chart at the moment, I don’t share the same views. As mentioned above, in my opinion, the declines that we’re seeing are actually an opportunity. The reason for this is relatively simple.
AEZS is working on a product known as Zoptrex. In fact, the company is in the midst of reviewing Phase 3 trial data. If the trial goes well, and I expect it to, Zoptrex will be proven to be a treatment for endometrial cancer. It is expected that the results from this trial will be released by the end of the year and that the company will submit an NDA for the treatment in the first half of next year.
Not only are things looking great for AEZS in the United States, they’re looking great abroad. At the end of the day, the NDA is likely to be submitted in the US early next year. However, the company has also signed a collaboration agreement that will allow it to penetrate the Australian and New Zealand markets.
What We’re Seeing From The Stock Today
Unfortunately, AEterna Zentaris is having a rough day in the market today. Currently (10:38), AEZS is trading at $4.37 per share after a loss of $0.18 per share, or 3.96%.
What We Can Expect To See Ahead
As you know by now, I’m not concerned about the declines. At the end of the day, AEZS is doing incredible things with Zoptrex, and I do believe that this product will launch the company into profitability. All in all, I’m expecting to see gains ahead.
Don’t waste your time! Click here to find winning trades in minutes!
Never Miss The News Again!
Do you want real-time, actionable market news delivered to your inbox? Subscribe to our mailing list below!
[Image Courtesy of Wikipedia]